Paper37489367
Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas.
Suzuki H and 5 others. Antibodies (Basel), 2023. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas. Papers, record 37489367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37489367
- Cell line
- CHO/CD44v3-108 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas.
- PubMed
Connected records3
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| JP22ama121008 (to Y.K.), JP22am0401013 (to Y.K.), JP22bm1004001 (to Y.K.), JP22ck0106730 (to Y.K.), and JP21am0101078 (to Y.K.) | Japan Agency for Medical Research and Development | PubMed | ||
| 21K20789 (to T.T.), 22K06995 (to H.S.), 21K07168 (to M.K.K.), and 22K07224 (to Y.K.) | Japan Society for the Promotion of Science | PubMed |
Source PubMed
References61
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34424761 | Development of a Novel Epitope Mapping System: RIEDL Insertion for Epitope Mapping Method. | Monoclon Antib Immunodiagn Immunother | 2021 | https://conductscience.org/library/papers/34424761 | PubMed |
| 2 | 7532175 | Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. | J Cell Biol | 1995 | https://conductscience.org/library/papers/7532175 | PubMed |
| 3 | 9003471 | Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. | Cancer Immunol Immunother | 1996 | https://conductscience.org/library/papers/9003471 | PubMed |
| 4 | 25894828 | Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. | Nat Med | 2015 | https://conductscience.org/library/papers/25894828 | PubMed |
| 5 | 11992408 | Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. | Int J Cancer | 2002 | https://conductscience.org/library/papers/11992408 | PubMed |
| 6 | 36660940 | Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models. | Int J Mol Med | 2023 | https://conductscience.org/library/papers/36660940 | PubMed |
| 7 | 35121863 | Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. | Nat Cancer | 2021 | https://conductscience.org/library/papers/35121863 | PubMed |
| 8 | 35628345 | Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35628345 | PubMed |
| 9 | 32117253 | CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. | Front Immunol | 2020 | https://conductscience.org/library/papers/32117253 | PubMed |
| 10 | 35991754 | Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma. | Mol Ther Oncolytics | 2022 | https://conductscience.org/library/papers/35991754 | PubMed |
| 11 | 37185762 | A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers. | Curr Issues Mol Biol | 2023 | https://conductscience.org/library/papers/37185762 | PubMed |
| 12 | 17062682 | A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/17062682 | PubMed |
| 13 | 33000243 | A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. | Oncol Rep | 2020 | https://conductscience.org/library/papers/33000243 | PubMed |
| 14 | 14320675 | THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. | Acta Pathol Microbiol Scand | 1965 | https://conductscience.org/library/papers/14320675 | PubMed |
| 15 | 35363934 | CD44v3,8-10 is essential for Slug-dependent vimentin gene expression to acquire TGF-β1-induced tumor cell motility. | Cancer Sci | 2022 | https://conductscience.org/library/papers/35363934 | PubMed |
| 16 | 1707342 | A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. | Cell | 1991 | https://conductscience.org/library/papers/1707342 | PubMed |
| 17 | 8652273 | Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. | Eur J Cancer | 1995 | https://conductscience.org/library/papers/8652273 | PubMed |
| 18 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 19 | 34944493 | CD44: A Multifunctional Mediator of Cancer Progression. | Biomolecules | 2021 | https://conductscience.org/library/papers/34944493 | PubMed |
| 20 | 29747682 | The biology and role of CD44 in cancer progression: therapeutic implications. | J Hematol Oncol | 2018 | https://conductscience.org/library/papers/29747682 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42955118 | The status quo and evolution of glycoconjugates for cancer immunotherapy. | Glycoconj J | 2026 | https://conductscience.org/library/papers/42955118 | PubMed |
| 38571347 | Exploring the Potentials of Hyaluronic Acid-coated Polymeric Nanoparticles in Enhanced Cancer Treatment by Precision Drug Delivery, Tackling Drug Resistance, and Reshaping the Tumour Micro Environment. | Curr Med Chem | 2025 | https://conductscience.org/library/papers/38571347 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCND1 | 595 | PubTator's text mining | https://conductscience.org/library/genes/595 | NCBI Gene |
| CD44 | 960 | PubTator's text mining | https://conductscience.org/library/genes/960 | NCBI Gene |
| DNMT3A | 1788 | PubTator's text mining | https://conductscience.org/library/genes/1788 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| FGFR2 | 2263 | PubTator's text mining | https://conductscience.org/library/genes/2263 | NCBI Gene |
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| FUT8 | 2530 | PubTator's text mining | https://conductscience.org/library/genes/2530 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
| PDPN | 10630 | PubTator's text mining | https://conductscience.org/library/genes/10630 | NCBI Gene |
| SLTM | 79811 | PubTator's text mining | https://conductscience.org/library/genes/79811 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37489367
GET https://conductscience.org/api/papers/v1/37489367/references?page=2